丁苯酞治疗缺血性脑卒中患者的临床研究

Clinical trial of butylphthalide in the treatment of patients with cerebral ischemic stroke

目的观察丁苯酞治疗缺血性脑卒中(CIS)患者的临床研究。方法将150例CIS患者随机分为对照组(75例)和试验组(75例)。对照组给予常规对症治疗,试验组在对照组的基础上给予丁苯酞,每次0.2 g,每天3次,口服。比较2组患者的临床疗效、认知功能评分、肝细胞生长因子(HGF)水平、复发情况和药物不良反应发生情况。结果治疗后,试验组总有效率为84.00%,显著高于对照组的66.67%(P<0.05)。治疗后,试验组和对照组的视空间功能评分分别为(4.52±0.39),(3.33±0.52)分,定向力评分分别为(5.31±0.55),(3.72±0.51)分,命名评分分别为(2.14±0.26),(1.47±0.33)分,选项评分分别为(3.97±0.21),(3.12±0.28)分,注意力评分分别为(4.58±0.31),(4.02±0.39)分,抽象能力评分分别为(1.35±0.19),(0.92±0.22)分,语言评分分别为(2.19±0.36),(1.26±0.42)分,血清HGF水平分别为(1356.25±141.21),(987.65±101.11)pg·mL-1,差异均有统计学意义(均P<0.05)。治疗后,试验组和对照组的药物不良反应发生率分别为9.33%,14.67%,差异无统计学意义(P>0.05)。试验组和对照组的复发率分别为10.67%,30.67%,差异有统计学意义(P<0.05)。结论在常规治疗基础上加用丁苯酞对CIS患者具有较好的临床疗效,显著改善CIS患者的认知功能障碍以及血清HGF水平,起到良好的脑保护作用,复发率低。

Objective To investigate the effect of butylphthalide in the treatment of patients with cerebral ischemic stroke(CIS). Methods A total of 150 patients with CIS were randomly divided into control group(75 cases) and treatment group(75 cases). Control group was given routine symptomatic treatment, treatment group was given butylphthalide, 0.2 g a time, 3 times a day oral, on the basis of control group. The clinical effect, score of cognitive function, the level of hepatocyte growth factor(HGF) and recurrence in two groups were compared. Results After treatment, the total effective rate in treatment group was 84.00%, significantly higher than that in control group, which was 66.67%(P<0.05). After treatment, the visual space function scores in treatment group and control group were(4.52±0.39),(3.33±0.52) points, the scores of directional force were(5.31±0.55),(3.72±0.51) points,the scores of name were(2.14±0.26),(1.47±0.33) points, the scores of option were(3.97±0.21),(3.12±0.28) points, attention scores were(4.58±0.31),(4.02±0.39) points, the abstract ability scores were( 1. 35 ± 0. 19),( 0. 92 ± 0. 22) points,the language scores were( 2. 19 ± 0. 36),( 1. 26 ± 0. 42) points,the serum HGF levels were( 1356. 25 ± 141. 21),( 987. 65 ± 101. 11) pg·mL-1,all with singnificant difference( all P < 0. 05). After treatment,the incidences of adverse drug reactions in treatment group and control group were9. 33%,14. 67%,without significant difference( P > 0. 05). The recurrence rates of control group and treatment group were 30. 67%,10. 67%,with significant difference( P < 0. 05). Conclusion Butylphthalide has a good clinical effect in the treatment of patients with CIS on the basis of routine treatment. It can significantly improve cognitive impairment and serum level of HGF in patients with CIS with brain protection and reduce recurrence rate.